United States

Home / Products / Cats & Dogs / Cytopoint / Efficacy

Print page content Print
Increase text size Decrease text size
Text Size
Cytopoint logo

This site is intended for U.S. animal healthcare professionals

Click here for Pet Owner Site

CYTOPOINT® treatment efficacy

CYTOPOINT® treatment efficacy

CYTOPOINT helps relieve atopic itch in dogs within 24 hours while giving skin time to heal after only one injection1

Fast, lasting canine itch relief

  • CYTOPOINT starts working in 24 hours, continues working for 4 to 8 weeks* after 1 injection to help reduce pruritus and lesions associated with canine atopic dermatitis1
Percentage of dogs with atopic dermatitis who had successful pruritus relief 1†
CYTOPOINT Canine Itch Relief Efficacy Chart
Mean pet owner-assessed VAS score1
CYTOPOINT VAS Efficacy Score Chart

Defining treatment success

  • Repeat administration every 4 to 8 weeks as needed in individual patients.1
  • Successful canine pruritus relief was defined as a reduction in pruritus score of ≥20 mm on the visual analog scale (VAS). VAS is an owner-assessed scale that measures itch along a continuum from normal dog (no itch) to extremely severe itch, using numbers from 0 to 100. VAS scoring instruments were given to owners, accompanied by explanations of how to record itch based on the behavior of the dog. Owners recorded itch on Days 1, 2, 3, 7 and every 7 days thereafter.1
  • Significantly different compared to placebo (P≤0.05).

CYTOPOINT gives damaged skin a chance to heal after 1 injection1

Percentage of dogs with atopic dermatitis who had successful improvement in skin condition1*
CYTOPOINT canine skin improvement
Mean veterinarian-assessed CADESI-03 score1
CADESI-03 scores after CYTOPOINT

See Coco’s CYTOPOINT story

Defining treatment success

  • Treatment success was defined as a ≥50% reduction from baseline in skin condition scores as assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and self-induced alopecia at 62 body sites.1
  • Significantly different compared to placebo (P≤0.05).
CADESI-O3 measures CYTOPOINT efficacy

Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

Reference: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2018 Zoetis Services LLC.  All rights reserved. CYT-00090R1